UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant x Filed by a Party Other Than the Registrant ¨
Check the Appropriate Box:
| | | | | | | | |
| ¨ | Preliminary Proxy Statement |
| |
| ¨ | Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) |
| |
| ¨ | Definitive Proxy Statement |
| |
| x | Definitive Additional Materials |
| |
| ¨ | Soliciting Material Pursuant to §240.14a-12 |
|
| Pfizer Inc. |
| (Name of Registrant as Specified In Its Charter) |
|
| (Name of Person(s) Filing Proxy Statement, if other than the Registrant) |
|
| Payment of filing fee (Check all boxes that apply): |
| |
| x | No fee required |
| |
| ¨ | Fee paid previously with preliminary materials |
| |
| ¨ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
| | |
On April 10, 2023, Pfizer Inc. posted the following message on Facebook: On April 10, 2023, Pfizer Inc. posted the following message on LinkedIn:
On April 10, 2023, Pfizer Inc. posted the following message via Display advertising: On April 10, 2023, Pfizer Inc. posted the following messages via Google ads: On April 10, 2023, Pfizer Inc. posted the following messages via native advertising:
On April 10, 2023, Pfizer Inc. posted the following message via Yahoo!Finance: On April 10, 2023, Pfizer Inc. posted the following message via email advertising:
